Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study will test the ability of a specially designed monoclonal antibody to destroy
multiple myeloma cells. This antibody is unique in its ability to promote the death of
multiple myeloma cells by processes known as antibody dependent cellular cytotoxicity
(ADCC)and complement dependent cytotoxicity (CDC). The study is designed to determine both
the optimal dose of the antibody to destroy multiple myeloma cells and frequency of dosing.